EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A dual-switch safety system enables safety controllability and high-efficiency enrichment for T cell immunotherapy

Hongtao Liu, Huimin Wang, Bo Hou, Wenxin Zhou, Hanfei Zhu, Xin Lin, Jiasheng Wang

Molecular Therapy Advances · 2026-12 · 34 (4) · 201865

DOI: 10.1016/j.omta.2026.201865 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy Advances, 2026-12. Verfasst von Hongtao Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Changping Laboratory, Yard 28, Science Park Road, Changping District, Beijing 102206, China. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T cell therapy has achieved durable and complete responses in a substantial proportion of patients with B cell malignancies. However, during CAR-T cell therapy, the occurrence of adverse events-including on-target/off-tumor toxicity against healthy tissues, cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and the risk of T cell malignancies arising from random genomic integration of viral vectors-significantly threatens patient safety. In this study, we developed a novel truncated HER2 (tHER2)-herpes simplex virus thymidine kinase (HSVTK) dual-switch safety system and site-specifically integrated it into the PDCD1 locus using a Cas12a/adeno-associated virus (AAV)-mediated delivery platform. Importantly, this dual-switch system enables efficient magnetic bead-based enrichment of tHER2-HSVTK (tHER2-TK)-positive T cells, allows tunable modulation of engineered T cell persistence through Herceptin or the small-molecule drug ganciclovir (GCV), and also provides a highly effective purification method before infusion. Collectively, these features enhance safety without compromising therapeutic efficacy, facilitating the development of safer and more controllable engineered T cell immunotherapies.

Schlagwörter

Stichwörter der Autor:innen

T cell immunotherapyenrichmentsafety-controllablesuicide switchtHER2-TK

Autor:innen und Institutionen

  • Changping Laboratory, Yard 28, Science Park Road, Changping District, Beijing 102206, China.
  • School of Basic Medical Sciences, Tsinghua University, Beijing 100084, China.
  • Department of Chemical Engineering, Tsinghua University, Beijing 100084, China.
  • Yifei (Hangzhou) Bio-tech Co., Ltd, Hangzhou 311305, China.
  • Tsinghua-Peking Center for Life Sciences, Tsinghua University, Beijing 10084, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Liu, H., Wang, H., Hou, B., Zhou, W., Zhu, H., Lin, X., & Wang, J. (2026). A dual-switch safety system enables safety controllability and high-efficiency enrichment for T cell immunotherapy. Molecular Therapy Advances, 34(4), 201865. https://doi.org/10.1016/j.omta.2026.201865

Vancouver

Liu H, Wang H, Hou B, Zhou W, Zhu H, Lin X, et al. A dual-switch safety system enables safety controllability and high-efficiency enrichment for T cell immunotherapy. Molecular Therapy Advances. 2026;34(4):201865. doi:10.1016/j.omta.2026.201865

BibTeX
@article{Liu2026,
  author = {Liu, Hongtao and Wang, Huimin and Hou, Bo and Zhou, Wenxin and Zhu, Hanfei and Lin, Xin and Wang, Jiasheng},
  title = {A dual-switch safety system enables safety controllability and high-efficiency enrichment for T cell immunotherapy},
  journal = {Molecular Therapy Advances},
  year = {2026},
  volume = {34},
  number = {4},
  pages = {201865},
  doi = {10.1016/j.omta.2026.201865}
}
Kostenlos starten →